P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor

CCUR > College of Education > Department of Education > journal articles > Item 987654321/29231

Please use this identifier to cite or link to this item: https://irlib.pccu.edu.tw/handle/987654321/29231

Title:	P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor
Authors:	Hsieh, Ya-Ju Hwu, Luen Chen, Yi-Chieh Ke, Chien-Chih Chen, Fu-Du Wang, Hsin-Ell Lin, Kang-Ping Yeh, Hsin-Hsien Chang, Chi-Wei Liu, Ren-Shyan
Contributors:	教育學系
Keywords:	HSV1-tk histone deacetylase inhibitor F-18-FHBG p21 PET
Date:	2014-04
Issue Date:	2015-01-27 11:27:37 (UTC+8)
Abstract:	Overexpressed histone deacetylase (HDAC) activity has been linked with tumor initiation and progression that prompt the development of histone deacetylase inhibitors (HDACIs) as anticancer agents. HDACI was reported to be able to activate p21 promoter through the SP1 binding sites in the proximal region of p21(WAF1/CIP1) promoter. In this study, we established a p21(WAF1/CIP1) promoter-driven triple-fused reporter gene system (p21-3H) to evaluate the efficacy of HDACI and the ganciclovir (GCV)-mediated anticancer effect contributed by HDACI-induced and p21-driven truncated herpes simplex virus-1 thymidine kinase sr39 mutant (ttksr39) in vitro and in vivo. Methods: The p21-3H construct was generated and stably or transiently transfected into H1299 cell lines. These cells were treated with trichostatin A or vorinostat (suberoylanilide hydroxamic acid [SAHA]) to evaluate the activation of p21 promoter-driven reporter gene expression by in vitro confocal fluorescence microscopy, luciferase assay, 2'-fluoro2'- deoxyarabinofuranosyl-5-ethyluracil (H-3-FEAU) cellular uptake, in vivo bioluminescence imaging, and 9-(4-F-18-fluoro-3-hydroxymethyl-butyl) guanine (F-18-FHBG) small-animal PET imaging. The therapeutic efficacy on p21-3H-expressing tumor xenografts was assessed by daily administration with SAHA (100 mg/kg intraperitoneally) or GCV (20 mg/kg) for 9 d, followed by tumor volume measurement. Results: On treatment with trichostatin A or SAHA, H1299 cells carrying p21-3H showed a significant increase of luciferase activity, cellular uptake of H-3-FEAU (Moravek), and DsRed expression. In vivo tumor xenografts carrying p21-3H also showed increased luciferase activity by luminescent imaging and enhanced accumulation of 18F-FHBG by small-animal PET imaging. Furthermore, when cells transfected with p21-3H or p21/PstI-3H (which lacks p53-binding sites) were treated, the increase of luciferase activity was similar in both groups, indicating that HDACI-induced p21 promoter activation is independent of p53. Both in vitro and in vivo results showed improved therapeutic effect by combined treatment of GCV and HDACI. Conclusion: We have established an HDACI-inducible, p21-driven reporter system that has the potential for evaluating the anticancer effect of HDACIs on cancer cells by multiple molecular imaging modalities. Furthermore, ttksr39 in a p21-3H reporter construct provides a potential combination with thymidine kinase-mediated gene therapy to optimize the therapeutic benefit of HDACI.
Relation:	JOURNAL OF NUCLEAR MEDICINE 卷: 55 期: 4 頁碼: 678-685
Appears in Collections:	[Department of Education ] journal articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	628	View/Open

View Licence

Loading...